Cascara Ventures

Cascara Ventures is the new investment fund of Adriaan Hart de Ruijter, experienced entrepreneur and investor in life sciences. Founded in 2016, Cascara invests in the seed stage of companies that apply technology to prevention, therapy and research. Examples are vaccines, medical devices, pharmaceuticals, imaging, software, medical data, robotics, healthcare services, diagnostics and cell therapy.

Adriaan Hart de Ruijter

Managing Director

12 past transactions

ATRO Medical

Venture Round in 2021
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise has created the base for the Trammpolin design and the development towards a prototype.

Surgify

Seed Round in 2017
Surgify are currently preparing the commercialization of a novel technology for bone surgery at Aalto University with financial support from Tekes (Finnish Funding Agency for Innovation). To enable continuous communication with clinicians, they have been working in close cooperation with Neurosurgical Department of Helsinki University Central Hospital, part of HUS (The Hospital District of Helsinki and Uusimaa).

ATRO Medical

Series A in 2017
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise has created the base for the Trammpolin design and the development towards a prototype.

Desentum

Series A in 2017
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.

microDimensions

Series A in 2016
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products that can be integrated into the existing customer workflow seamlessly.

Xbird

Seed Round in 2016
xbird is a provider of software solutions in the healthcare sector, founded in Berlin in 2015. The company uses artificial intelligence to personalize therapies for better results. Especially in diabetes therapy, the algorithms developed by xbird can record the behavior and lifestyle of patients using smartphones and other wearables. In this way, as part of holistic care, health risks can be identified and prevented and long-term treatment can be optimized.

Preventicus

Series A in 2016
Preventicus engineers products for smartphones and smartwatches that obtain health parameters without any extra accessories. It generates data conclusive to a degree previously only obtainable by physicians. Preventicus’ software applications are certified medical devices with an accuracy verified in clinical studies. Its primary product is a class I medical device. Preventicus is the creator of Preventicus Heartbeats, a smart screening solution that identifies atrial fibrillation for stroke prevention, based on technologies that are present in a standard smartphone or smartwatch. Preventicus was founded in 2014 by Thomas Hübner. It is based in Jena, Germany.

Fiagon

Series C in 2015
Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation. Fiagon's systems use electromagnetic tracking matrix algorithms and flexible pointer technology that indicates the position of the instrument used in the CT or MRI image data, allowing physicians to get accurate planning, improve patient outcomes, and implementation of the operation.

microDimensions

Seed Round in 2014
microDimensions produces innovative software solutions for the processing, analysis, and visualization of biomedical imagery, in particular on a cellular level. Employees of microDimensions continuously strive to create efficient algorithms fulfilling highest quality standards. A particular focus of the company is to offer software products that can be integrated into the existing customer workflow seamlessly.

Fiagon

Series B in 2012
Fiagon develops clinical navigation systems that reimagine image guidance by improving the function of electromagnetic navigation. Fiagon's systems use electromagnetic tracking matrix algorithms and flexible pointer technology that indicates the position of the instrument used in the CT or MRI image data, allowing physicians to get accurate planning, improve patient outcomes, and implementation of the operation.

SurgicEye

Series B in 2012
SurgicEye designs intra-operative imaging and instrument navigation solutions for surgical procedures. It offers a navigated radio-guided surgery based on the handheld 3-D freehand SPECT imaging technology called the declipse SPECT open surgery, an intraoperative 3D imaging system for invasive sentinel lymph node biopsy called the declipse SPECT Laparascopy, and a mobile SPECT imaging solution with a high resolution on a small footprint called the declipse SPECT imaging probe. The company also advises clients on medical device development, requirement engineering and software specification for medical devices, software development for medical devices, testing of software for medical devices, and support in the design and conduction of clinical studies. Dr. Jörg Traub founded SurgicEye in 2008, with its headquarters in Munich in Germany.

Meidrix Biomedicals

Series A in 2011
Meidrix Biomedicals is a medical biotechnology company that specializes in medical devices for cartilage repair. Meidrix Biomedicals also offers regenerative and biological medical products. Meidrix Biomedicals was founded in 2009 and was headquartered in Bayern, Germany.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.